Dendritic Cell Vaccine Trial Shows Promising Results

One year after his last treatment, a six-year-old boy with recurrent neuroblastoma is in complete remission for his high-risk metastatic cancer. Doctors reported this case study in the January 2013 issue of Pediatrics, theĀ journal of theĀ American Academy of Pediatrics.

The B+ Foundation and Solving Kids’ Cancer Jointly Funds a Novel Neuroblastoma Vaccine Trial

The Andrew McDonough B+ Foundation, a Delaware-based nonprofit, and NYC-based charity Solving Kids’ Cancer (SKC) announce their joint support of a clinical trial to test a new cancer vaccine against neuroblastoma – a common type of solid tumor that occurs in young children.